Impact of proteomics on bladder cancer research

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Impact of proteomics on bladder cancer research. / Celis, Julio E; Gromova, Irina; Moreira, José Manuel Alfonso; Cabezon, Teresa; Gromov, Pavel.

In: Pharmacogenomics, Vol. 5, No. 4, 2004, p. 381-94.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Celis, JE, Gromova, I, Moreira, JMA, Cabezon, T & Gromov, P 2004, 'Impact of proteomics on bladder cancer research', Pharmacogenomics, vol. 5, no. 4, pp. 381-94. https://doi.org/10.1517/14622416.5.4.381

APA

Celis, J. E., Gromova, I., Moreira, J. M. A., Cabezon, T., & Gromov, P. (2004). Impact of proteomics on bladder cancer research. Pharmacogenomics, 5(4), 381-94. https://doi.org/10.1517/14622416.5.4.381

Vancouver

Celis JE, Gromova I, Moreira JMA, Cabezon T, Gromov P. Impact of proteomics on bladder cancer research. Pharmacogenomics. 2004;5(4):381-94. https://doi.org/10.1517/14622416.5.4.381

Author

Celis, Julio E ; Gromova, Irina ; Moreira, José Manuel Alfonso ; Cabezon, Teresa ; Gromov, Pavel. / Impact of proteomics on bladder cancer research. In: Pharmacogenomics. 2004 ; Vol. 5, No. 4. pp. 381-94.

Bibtex

@article{bd94f9d40bc646658cf99f6551c0728c,
title = "Impact of proteomics on bladder cancer research",
abstract = "Detecting bladder cancer at an early stage and predicting how a tumor will behave and act in response to therapy, as well as the identification of new targets for therapeutic intervention, are among the main areas of research that will benefit from the current explosion in the number of powerful technologies emerging within proteomics. The purpose of this article is to briefly review what has been achieved to date using proteomic technologies and to bring forward novel strategies - based on the analysis of clinically relevant samples - that promise to accelerate the translation of basic discoveries into the daily clinical practice.",
keywords = "Animals, Drug Delivery Systems, Humans, Proteomics, Urinary Bladder Neoplasms",
author = "Celis, {Julio E} and Irina Gromova and Moreira, {Jos{\'e} Manuel Alfonso} and Teresa Cabezon and Pavel Gromov",
year = "2004",
doi = "10.1517/14622416.5.4.381",
language = "English",
volume = "5",
pages = "381--94",
journal = "Pharmacogenomics",
issn = "1462-2416",
publisher = "Future Medicine Ltd.",
number = "4",

}

RIS

TY - JOUR

T1 - Impact of proteomics on bladder cancer research

AU - Celis, Julio E

AU - Gromova, Irina

AU - Moreira, José Manuel Alfonso

AU - Cabezon, Teresa

AU - Gromov, Pavel

PY - 2004

Y1 - 2004

N2 - Detecting bladder cancer at an early stage and predicting how a tumor will behave and act in response to therapy, as well as the identification of new targets for therapeutic intervention, are among the main areas of research that will benefit from the current explosion in the number of powerful technologies emerging within proteomics. The purpose of this article is to briefly review what has been achieved to date using proteomic technologies and to bring forward novel strategies - based on the analysis of clinically relevant samples - that promise to accelerate the translation of basic discoveries into the daily clinical practice.

AB - Detecting bladder cancer at an early stage and predicting how a tumor will behave and act in response to therapy, as well as the identification of new targets for therapeutic intervention, are among the main areas of research that will benefit from the current explosion in the number of powerful technologies emerging within proteomics. The purpose of this article is to briefly review what has been achieved to date using proteomic technologies and to bring forward novel strategies - based on the analysis of clinically relevant samples - that promise to accelerate the translation of basic discoveries into the daily clinical practice.

KW - Animals

KW - Drug Delivery Systems

KW - Humans

KW - Proteomics

KW - Urinary Bladder Neoplasms

U2 - 10.1517/14622416.5.4.381

DO - 10.1517/14622416.5.4.381

M3 - Journal article

C2 - 15165174

VL - 5

SP - 381

EP - 394

JO - Pharmacogenomics

JF - Pharmacogenomics

SN - 1462-2416

IS - 4

ER -

ID: 41043813